

Altus Pharmaceuticals Inc.  
Form 8-K  
April 02, 2008

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

April 2, 2008

**Altus Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

Delaware

0-51711

04-3573277

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

640 Memorial Drive, Cambridge,  
Massachusetts

02139

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

617-299-2900

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 1.02 Termination of a Material Definitive Agreement.**

On October 29, 2007, Altus Pharmaceuticals, Inc. ("Altus") announced that it had notified Rizika Realty Trust, the landlord (the "Landlord") under Altus' lease for 125 Sidney Street, Cambridge, Massachusetts (the "Sidney Street Lease") that Altus was terminating the Sidney Street Lease effective November 30, 2008. On April 2, 2008, Altus and the Landlord agreed that the 125 Sidney Street Lease would terminate as of March 31, 2008. In connection with the termination, Altus has agreed to pay the Landlord a lease termination fee in the amount of \$55,000.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Altus Pharmaceuticals Inc.

*April 2, 2008*

*By: Jonathan I. Lieber*

---

*Name: Jonathan I. Lieber*

*Title: Vice President, Chief Financial Officer and Treasurer*

---

**Top of the Form**

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
10.1	Lease Termination Agreement